
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT
- About


Prothena Corporation plc (PRTA)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: PRTA (1-star) is currently NOT-A-BUY. Pass it for now.
1 Year Target Price $24.29
1 Year Target Price $24.29
5 | Strong Buy |
3 | Buy |
2 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -24.41% | Avg. Invested days 16 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 328.88M USD | Price to earnings Ratio - | 1Y Target Price 24.29 |
Price to earnings Ratio - | 1Y Target Price 24.29 | ||
Volume (30-day avg) 10 | Beta -0.08 | 52 Weeks Range 4.32 - 25.42 | Updated Date 06/30/2025 |
52 Weeks Range 4.32 - 25.42 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.04 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -79.94% | Operating Margin (TTM) -2318.99% |
Management Effectiveness
Return on Assets (TTM) -15.49% | Return on Equity (TTM) -23.46% |
Valuation
Trailing PE - | Forward PE 64.1 | Enterprise Value -81002220 | Price to Sales(TTM) 2.38 |
Enterprise Value -81002220 | Price to Sales(TTM) 2.38 | ||
Enterprise Value to Revenue 2.82 | Enterprise Value to EBITDA -3.58 | Shares Outstanding 53827000 | Shares Floating 40657673 |
Shares Outstanding 53827000 | Shares Floating 40657673 | ||
Percent Insiders 19.01 | Percent Institutions 74.25 |
Analyst Ratings
Rating 4 | Target Price 24.29 | Buy 3 | Strong Buy 5 |
Buy 3 | Strong Buy 5 | ||
Hold 2 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Prothena Corporation plc

Company Overview
History and Background
Prothena Corporation plc is a late-stage clinical biotechnology company focused on the discovery and development of novel therapies to treat diseases that involve protein misfolding or cell adhesion. Founded in 2012 as a spin-off from Elan Corporation, Prothena initially focused on Alzheimer's disease and Parkinson's disease. Over time, it has expanded its pipeline to include therapies for other neurodegenerative and rare peripheral amyloid diseases.
Core Business Areas
- Neurodegenerative Diseases: Development of therapies targeting neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.
- Peripheral Amyloid Diseases: Development of therapies for rare peripheral amyloid diseases like AL amyloidosis and ATTR amyloidosis.
Leadership and Structure
Gene Kinney, Ph.D., is the President and Chief Executive Officer. The company has a standard corporate structure with a board of directors and various executive leadership positions overseeing research and development, clinical operations, and business development.
Top Products and Market Share
Key Offerings
- Birtamimab (PRX004): A monoclonal antibody designed to neutralize soluble amyloid light chain (AL) protein aggregates in AL amyloidosis. Phase 3 PRONTO study did not meet primary endpoint. Competitors include Johnson & Johnson (Tremfya) and Takeda (Vyvgart). As of November 2024, no market share is available as the drug is not approved.
- PRX012: A potential best-in-class high potency anti-amyloid beta (Au03b2) antibody in development for the treatment of Alzheimeru2019s disease. Clinical trials are ongoing. Competitors include Eisai/Biogen (Leqembi), Eli Lilly (Donanemab). Market share is not applicable at this development stage.
Market Dynamics
Industry Overview
The biotechnology industry focused on neurodegenerative and rare diseases is characterized by high risk, long development timelines, and substantial investment. The market for Alzheimer's disease and Parkinson's disease therapies is large and growing due to an aging population. The market for rare diseases is smaller but offers opportunities for orphan drug designation and premium pricing.
Positioning
Prothena is positioned as a company focused on developing novel therapies using its expertise in protein misfolding and cell adhesion. It aims to differentiate itself through innovative approaches and targeting specific disease mechanisms.
Total Addressable Market (TAM)
The TAM for Alzheimer's and Parkinson's diseases alone is estimated to be tens of billions of dollars annually. Prothena is aiming to capture a significant portion of this market with its PRX012 and other pipeline assets. The TAM for AL amyloidosis is smaller, but still significant due to high unmet need. The PRONTO study results will determine if Prothena can capture that portion of the market.
Upturn SWOT Analysis
Strengths
- Strong scientific expertise in protein misfolding and cell adhesion
- Innovative pipeline of novel therapies
- Experienced management team
- Focus on unmet medical needs
Weaknesses
- High reliance on clinical trial outcomes
- Limited commercial infrastructure
- Dependence on partnerships for funding and development
- Recent Phase 3 Trial failure
Opportunities
- Potential for breakthrough therapies in Alzheimer's disease and Parkinson's disease
- Expansion of pipeline through strategic collaborations and acquisitions
- Orphan drug designation for rare disease programs
- Positive clinical results could lead to significant revenue growth
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established pharmaceutical companies
- Patent challenges
- Uncertainty of R&D investment returns
Competitors and Market Share
Key Competitors
- ESAI (ESALY)
- LLY (LLY)
- BIIB (BIIB)
- JNJ (JNJ)
- TAK (TAK)
Competitive Landscape
Prothena faces strong competition from large pharmaceutical companies with established pipelines and commercial infrastructure. Its competitive advantage lies in its novel therapeutic approaches and expertise in protein misfolding. Market share for amyloidosis treatment is divided by competitors. Market share related to AD is rapidly evolving and dependent on safety and efficacy of treatments.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been dependent on preclinical results and partnership collaborations.
Future Projections: Future growth is largely dependent on clinical trial results for PRX012 and other pipeline assets. Analyst estimates vary widely based on perceived probability of success.
Recent Initiatives: Focus on advancing PRX012 into late-stage clinical trials and expanding partnerships to fund development programs.
Summary
Prothena is a clinical-stage biotech firm with a focus on high-risk, high-reward therapies for neurodegenerative and rare diseases. Its innovative approach to protein misfolding offers promise, but it relies heavily on successful clinical trials. Recent negative data for Birtamimab will impact the company valuation until new, positive data arises. Continued partnership and R&D execution are critical for future growth, while competition from large pharmaceuticals remains a significant challenge.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
Disclaimers:
The data provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Prothena Corporation plc
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2012-12-21 | President, CEO & Director Dr. Gene G. Kinney Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 163 | Website https://www.prothena.com |
Full time employees 163 | Website https://www.prothena.com |
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. Its product pipeline include Prasinezumab, an investigational humanized monoclonal antibody which is in phase 2b clinical trial, as well as phase 1 and 2 clinical trials for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in phase 2 clinical trial for potential treatment of transthyretin amyloidosis; BMS-986446, an investigational antibody, which is in phase 2 clinical trial to treat Alzheimer's disease; PRX012, an investigational antibody, which is in phase 1 clinical trial to treat Alzheimer's disease; PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease; and PRX019, an investigational antibody, which is in phase 1 clinical trial for the potential treatment of neurodegenerative diseases. It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.